2017
Management of myelofibrosis: JAK inhibition and beyond
Stahl M, Zeidan AM. Management of myelofibrosis: JAK inhibition and beyond. Expert Review Of Hematology 2017, 10: 459-477. PMID: 28395559, DOI: 10.1080/17474086.2017.1317590.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsBone marrow fibrosisMarrow fibrosisAbnormal cytokine expressionClinical trial evidenceJAK2 V617F allele burdenErythropoiesis stimulating agentsNovel therapeutic optionsAnti-fibrosis agentsV617F allele burdenJAK2 inhibitor ruxolitinibNovel therapeutic agentsJAK2 V617F mutationConstitutional symptomsCytoreductive drugsSymptom burdenImmunomodulatory drugsSurvival improvementJAK1/2 inhibitorMF patientsTherapeutic optionsTrial evidenceCytokine expressionExtramedullary hematopoiesisPrognostic assessmentRuxolitinib monotherapy
2016
Update on acute myeloid leukemia stem cells: New discoveries and therapeutic opportunities
Stahl M, Kim TK, Zeidan AM. Update on acute myeloid leukemia stem cells: New discoveries and therapeutic opportunities. World Journal Of Stem Cells 2016, 8: 316-331. PMID: 27822339, PMCID: PMC5080639, DOI: 10.4252/wjsc.v8.i10.316.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsLeukemia stem cellsNormal hematopoietic stem cellsHematopoietic stem cellsAcute myeloid leukemia stem cellsMyeloid leukemia stem cellsStem cellsAcute myeloid leukemiaMultitude of drugsNovel therapeutic agentsCancer stem cellsClinical trialsMyeloid leukemiaTherapeutic windowSelf-renewal pathwaysXenograft modelClinical developmentTherapeutic opportunitiesRational targetTherapeutic agentsLSC biologyAcceptable therapeutic windowDrugsCellsFunctional studiesLeukemia